MIASMA: Asthma exacerbation reduction with salmeterol [2]

Chest

Volumn 121, Issue , 2002, Pages 1002-1003

  Shrewsbury, Stephen B ^a   Pyke, Stephen ^b  

^a GLAXOSMITHKLINE   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; FLUTICASONE; FLUTICASONE PLUS SALMETEROL; FLUTICASONE PROPIONATE; FORMOTEROL; SALMETEROL; STEROID; UNCLASSIFIED DRUG;

ASTHMA; CLINICAL TRIAL; DISEASE CONTROL; DISEASE EXACERBATION; DRUG EFFECT; EOSINOPHIL; HUMAN; LETTER; LUNG FUNCTION; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-AGONISTS; ALBUTEROL; ASTHMA; GLUCOCORTICOIDS; HUMANS;

EID: 0036210308     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.121.3.1002     Document Type: Letter

References (6)

1. M Sears Deleterious effects of inhaled β-agonists: short-acting and long-acting agents differ Chest 2001 1297 1299
2. S Shrewsbury S Pyke M Britton Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA) BMJ 320 2001 1368 1373
3. J Matz A Emmett K Richard Addition of salmeterol to low-dose fluticasone versus higher-dose fluticasone: an analysis of asthma exacerbations J Allergy Clin Immunol 107 2001 783 789
4. RA McIvor E Pizzichini MO Turner Potential masking effects of salmeterol on airway inflammation in asthma Am J Respir Crit Care Med 158 1998 924 930
5. 2-agonist, assessed in airway biopsies and bronchoalveolar lavage in asthma Am J Respir Crit Care Med 160 1999 1493 1499
6. M Sue-Chu A Wallin S Wilson Bronchial biopsy study in asthmatics treated with low- and high-dose fluticasone propionate (FP) compared to low-dose FP combined with salmeterol [abstract] Eur Respir J S30 1999 124s